Iovance Biotherapeutics (NASDAQ:IOVA) Raised to Market Outperform at Citizens Jmp

Iovance Biotherapeutics (NASDAQ:IOVA) was upgraded by Citizens Jmp from a “market perform” rating to a “market outperform” rating in a research report issued to clients and investors on Wednesday, MarketBeat.com reports. The firm currently has a $5.00 target price on the biotechnology company’s stock. Citizens Jmp’s target price points to a potential upside of 32.28% from the company’s current price.

IOVA has been the subject of a number of other research reports. Chardan Capital reduced their price target on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a report on Thursday, November 6th. HC Wainwright decreased their price objective on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating on the stock in a report on Wednesday, October 29th. Barclays lifted their target price on shares of Iovance Biotherapeutics from $9.00 to $10.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Finally, The Goldman Sachs Group restated a “sell” rating and set a $2.00 price target on shares of Iovance Biotherapeutics in a research report on Thursday, February 5th. Six research analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat.com, Iovance Biotherapeutics presently has an average rating of “Hold” and an average price target of $10.00.

Iovance Biotherapeutics Trading Up 30.8%

Iovance Biotherapeutics stock opened at $3.78 on Wednesday. The firm has a market cap of $1.50 billion, a PE ratio of -3.15 and a beta of 0.76. Iovance Biotherapeutics has a 12 month low of $1.64 and a 12 month high of $5.64. The stock’s 50 day simple moving average is $2.64 and its two-hundred day simple moving average is $2.40.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its earnings results on Tuesday, February 24th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. Iovance Biotherapeutics had a negative net margin of 158.78% and a negative return on equity of 55.24%. The firm had revenue of $86.77 million during the quarter, compared to analyst estimates of $81.61 million. On average, equities research analysts forecast that Iovance Biotherapeutics will post -1.24 EPS for the current year.

Hedge Funds Weigh In On Iovance Biotherapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Iovance Biotherapeutics by 13.1% during the fourth quarter. Vanguard Group Inc. now owns 27,207,079 shares of the biotechnology company’s stock worth $74,275,000 after buying an additional 3,148,096 shares in the last quarter. State Street Corp grew its holdings in shares of Iovance Biotherapeutics by 51.5% in the 4th quarter. State Street Corp now owns 20,161,445 shares of the biotechnology company’s stock worth $55,041,000 after acquiring an additional 6,851,486 shares during the period. Invenomic Capital Management LP increased its stake in Iovance Biotherapeutics by 13.5% in the 4th quarter. Invenomic Capital Management LP now owns 11,959,505 shares of the biotechnology company’s stock valued at $32,649,000 after purchasing an additional 1,417,897 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in Iovance Biotherapeutics by 30.9% during the fourth quarter. Goldman Sachs Group Inc. now owns 8,607,564 shares of the biotechnology company’s stock worth $23,499,000 after purchasing an additional 2,032,062 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Iovance Biotherapeutics by 16.4% during the 4th quarter. Geode Capital Management LLC now owns 7,991,640 shares of the biotechnology company’s stock valued at $21,821,000 after acquiring an additional 1,123,337 shares in the last quarter. 77.03% of the stock is owned by institutional investors and hedge funds.

More Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: FDA approved lifileucel (Amtagvi) for metastatic melanoma, shifting the program from a pipeline bet to a commercialization and execution test; company cites favorable real‑world response/safety data and Fast Track status in 2L non‑small cell lung cancer — larger label/indication opportunities and regulatory momentum support adoption and revenue upside. Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test
• Positive Sentiment: Positive pilot TIL trial results in advanced soft‑tissue sarcomas (50% objective response rate reported) from an MSKCC‑led study — expands Amtagvi’s addressable indications and appears to be the immediate catalyst behind heavy buying and the stock jump. Iovance Announces Positive Results from the First Clinical Trial for TIL Cell Therapy in Soft Tissue Sarcomas
• Positive Sentiment: Q4 2025 results beat: revenue ~$86.8M (above estimates), EPS loss narrower than expected and management cites ~30% revenue growth and improving gross margins — supports the thesis that commercialization of Amtagvi is ramping and moves the company closer to profitability. Iovance outlines surge toward profitability with 30% revenue growth in Q4 2025
• Neutral Sentiment: Analyst coverage and bullish notes are arriving (some price targets and a higher “floor” rating) reflecting better margins and faster turnaround assumptions, but firms still flag high risk — sentiment lift but tempered by execution risk. Better Gross Margin And Faster Turnaround Support A Higher Floor (Rating Upgrade)
• Neutral Sentiment: Unusual options activity — heavy call buying (large increase vs. normal volume) indicates speculative positioning that can amplify intraday moves in either direction. (No direct article link — reported market activity.)
• Negative Sentiment: Company remains unprofitable with a deeply negative net margin and negative ROE; analysts note cash runway into mid‑2027 and material dilution risk since Amtagvi is not expected to be cash‑positive immediately — execution, manufacturing scale and potential fundraising are key downside risks. Iovance stock profile and Q4 metrics
• Negative Sentiment: Operational challenges remain — manufacturing scale, wider adoption outside specialized centers and the need for expanded registrational trials could delay revenue visibility and increase costs, keeping upside conditional on successful execution. Iovance FDA Approval Shifts Lifileucel From Pipeline Bet To Execution Test

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company’s lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance’s pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance’s TIL platform harnesses a patient’s own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.